Women's Health

Close monitoring for dnPPHTN during the first 2 weeks post-delivery is highly recommended for women determined to be at high risk for the hypertensive disorder of pregnancy.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.

The USPSTF recommends all women ages 65 and older and at-risk postmenopausal women under 65 should be screened for osteoporosis.

FDA action date set for July 26, 2025.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Atumelnant treatment resulted in statistically significant reductions in serum androstenedione and 17-OHP as well as notable improvements in CAH symptoms.

Elinzanetant produced a statistically significant reduction in frequency of treatment-related vasomotor symptoms as early as week 1 and in severity at weeks 4 and 12.

Your daily dose of the clinical news you may have missed.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

The addition, based on an approved update to labeling, expands to 4 the recommended vaccination options that health care professionals can offer to pregnant people.

The potential adverse outcomes include asthma, food allergies, cerebral palsy, and cancer, according to a recent systematic review and meta-analysis.

Your daily dose of the clinical news you may have missed.

How does alcohol figure in to American holiday celebrations? We checked with Alcohol.org for this quiz. Are answers what you expect?

Comments on the draft recommendation can be submitted through December 23, 2024.

At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.

The recommendations from WikiGuidelines are the first for UTI prevention, diagnosis, and management in over a decade.

von Willebrand disease affects up to 1% of the population yet diagnosis is delayed an average of 16 years after onset of symptoms, especially in women.

Your daily dose of the clinical news you may have missed.

The new e-commerce partnership expands access to Opill by allowing direct delivery of the contraceptive to consumers' homes without a prescription.

Oral sulopenem is the first oral penem approved in the US for treating uUTIs in women with limited options.

The safety data used to update the Flublok label is from a study of more than 48 000 pregnant women across multiple flu seasons, according to Sanofi.

Bayer announced 12 presentations focused on symptoms of menopause and effects of its investigational oral nonhormonal medication elinzanetant.

Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.

The FDA today accepted GSK's NDA for gepotidacin for the treatment of uncomplicated urinary tract infections in women and adolescents.

Even after adjusting for breast density, studies reveal a significantly greater risk for a cancer diagnosis within 2 decades. A UC Davis expert offers details.

A false positive finding on a screening mammogram is fairly common, according to UC Davis biostatistician Diana Miglioretti, PhD. Here's why.

The group of women least likely to return for a regular preventive screening mammogram after a false positive result surprised this primary investigator.

The elinzanetant NDA is based on data, including long-term efficacy, from the OASIS phase 3 clinical trial program, according to Bayer.